Showing 1 - 1 of 1
We examine the effect of competitive shocks on executive compensation in the pharmaceutical sector. When a pharmaceutical firm receives a breakthrough therapy designation (BTD), its rivals respond by increasing option-based compensation for CEOs and other executives. The rivals also escalate...
Persistent link: https://www.econbiz.de/10014237847